A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer

European Journal of Cancer

Volumn 46, Issue 5, 2010, Pages 885-891

  Yun, Jina ^a   Lee, Jeeyun ^a   Park, Se Hoon ^a   Park, Joon Oh ^a   Park, Young Suk ^a   Lim, Ho Yeong ^a   Kang, Won Ki ^a  

^a Samsung Medical Center   (South Korea)

Author keywords

Capecitabine; Cisplatin; Epirubicin; Stomach cancer

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 77349105561     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.12.015     Document Type: Article

References (21)

1. Won Y.J., Sung J., Jung K.W., et al. Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat 41 3 (2009) 122-131
2. Pyrhonen S., Kuitunen T., Nyandoto P., and Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Brit J Cancer 71 3 (1995) 587-591
3. Glimelius B., Ekstrom K., Hoffman K., et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8 2 (1997) 163-168
4. Ohtsu A., Yoshida S., and Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 24 14 (2006) 2188-2196
5. Wagner A.D., Grothe W., Haerting J., Kleber G., Grothey A., and Fleig W.E. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24 18 (2006) 2903-2909
6. Twelves C. Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? Oncology (Williston Park) 2002;16(12 Suppl no. 14):23-6.
7. Hong Y.S., Song S.Y., Lee S.I., et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 15 9 (2004) 1344-1347
8. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. New Engl J Med 358 1 (2008) 36-46
9. Kang Y.K., Kang W.K., Shin D.B., et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20 4 (2009) 666-673
10. Okines A.F., Norman A.R., McCloud P., Kang Y.K., and Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 20 9 (2009) 1529-1534
11. Cho E.K., Lee W.K., Lim D.Y., et al. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma. J Korean Med Sci 17 3 (2002) 348-352
12. Cho E.K., Lee W.K., Im S.A., et al. A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer. Oncology 68 4-6 (2005) 333-340
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-16.
14. Webb A., Cunningham D., Scarffe J.H., et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15 1 (1997) 261-267
15. Ross P., Nicolson M., Cunningham D., et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20 8 (2002) 1996-2004
16. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24 31 (2006) 4991-4997
17. Kim T.W., Kang Y.K., Ahn J.H., et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 13 12 (2002) 1893-1898
18. Lee J., Lim T., Uhm J., et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 18 5 (2007) 886-891
19. Starling N., Rao S., Cunningham D., et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 27 23 (2009) 3786-3793
20. Al-Batran S.E., Hartmann J.T., Probst S., et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26 9 (2008) 1435-1442
21. Cvitkovic E. Ongoing and unsaid on oxaliplatin: the hope. Brit J Cancer 77 Suppl 4 (1998) 8-11